Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of NewLink Genetics Corporation (NASDAQ: NLNK) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of NewLink Genetics Corporation (NASDAQ: NLNK) concerning whether a series of statements by NewLink Genetics Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 9, 2016, NewLink revealed that the Company's experimental pancreatic cancer immunotherapy algenpantucel-L did not meet the main goal in a late-stage study.  Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's phase III trial, compared to median survival of 30.4 months for patients treated with standard therapy.

Following this news, NASDAQ: NLNK shares dropped 38.48% on May 9, 2016.

Based in Ames, Iowa, and founded in 1999 NewLink Genetics Corporation is engaged in discovering, developing, and commercializing immunotherapeutic products for patients with cancer.

If you purchased shares of NewLink Genetics Corporation (NASDAQ: NLNK) on or before May 9, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185